Last updated on February 2019

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)


Brief description of study

The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.

Detailed Study Description

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), 2) time from first day of hematopoietic cell infusion to randomization (30-60 days vs. 61-90 days) and 3) presence vs absence of or unknown minimal residual disease (MRD) from the most recent pre-registration bone marrow (BM) aspirate.

Clinical Study Identifier: NCT02997202

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Global Development

Site AU61001
Liverpool, Australia
  Connect »

Astellas Pharma Global Development

Site DK45001
Copenhagen, Denmark
  Connect »

Astellas Pharma Global Development

Site DE49009
Stuttgart, Germany
  Connect »

Astellas Pharma Global Development

Site JP81019
Kagoshima-shi, Japan
  Connect »

Astellas Pharma Global Development

Site JP81012
Nishinomiya, Japan
  Connect »

Astellas Pharma Global Development

Site JP81005
Osaka City, Japan
  Connect »

Astellas Pharma Global Development

Site JP81008
Shimotsuke, Japan
  Connect »

Astellas Pharma Global Development

Site KR82001
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82002
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82003
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82004
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82005
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site TW88601
Kaohsiung, Taiwan
  Connect »

Astellas Pharma Global Development

Northside
Atlanta, GA United States
  Connect »

Astellas Pharma Global Development

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

Astellas Pharma Global Development

Baylor College of Medicine
Houston, TX United States
  Connect »

Astellas Pharma Global Development

Fred Hutchinson Cancer Research Center
Seattle, WA United States
  Connect »

Astellas Pharma Global Development

Site AU61002
Melbourne, Australia
  Connect »

Astellas Pharma Global Development

Site AU61004
Westmead, Australia
  Connect »

Astellas Pharma Global Development

Site BE32003
Bruxelles, Belgium
  Connect »

Astellas Pharma Global Development

Site FR33002
Toulouse Cedex 9, France
  Connect »

Astellas Pharma Global Development

Site FR33010
Vandoeuvre-Les-Nancy, France
  Connect »

Astellas Pharma Global Development

Site DE49003
Halle (Saale), Germany
  Connect »

Astellas Pharma Global Development

Site JP81010
Sendai-shi, Japan
  Connect »

Astellas Pharma Global Development

Site GB44003
Bristol, United Kingdom
  Connect »

Astellas Pharma Global Development

Site GB44004
London, United Kingdom
  Connect »

Astellas Pharma Global Development

Stanford University
Stanford, CA United States
  Connect »

Astellas Pharma Global Development

H. Lee Moffitt Cancer Center
Tampa, FL United States
  Connect »

Astellas Pharma Global Development

Massachusetts General Hospital
Boston, MA United States
  Connect »

Astellas Pharma Global Development

Ohio State University, The
Columbus, OH United States
  Connect »

Astellas Pharma Global Development

West Virginia University Hospital
Morgantown, WV United States
  Connect »

Astellas Pharma Global Development

Site FR33006
Montpellier Cedex 5, France
  Connect »

Astellas Pharma Global Development

Site GR30001
Thessaloniki, Greece
  Connect »

Astellas Pharma Global Development

Rush University Medical Center
Chicago, IL United States
  Connect »

Astellas Pharma Global Development

Tufts Medical Center
Boston, MA United States
  Connect »

Astellas Pharma Global Development

University of Nebraska Medical Center
Omaha, NE United States
  Connect »

Astellas Pharma Global Development

University Hospitals of Cleveland Medical Center
Cleveland, OH United States
  Connect »

Astellas Pharma Global Development

Site GB44010
Birmingham, United Kingdom
  Connect »

Astellas Pharma Global Development

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Astellas Pharma Global Development

University of Kansas Medical Center
Kansas City, KS United States
  Connect »

Astellas Pharma Global Development

University of Massachusetts
Worcester, MA United States
  Connect »

Astellas Pharma Global Development

University of Minnesota School of Medicine
Minneapolis, MN United States
  Connect »

Astellas Pharma Global Development

Washington University in St. Louis
Saint Louis, MO United States
  Connect »

Astellas Pharma Global Development

Memorial Sloan Kettering
New York, NY United States
  Connect »

Astellas Pharma Global Development

Duke University Medical Center
Durham, NC United States
  Connect »

Astellas Pharma Global Development

University of Wisconsin Hospital and Clinics
Madison, WI United States
  Connect »

Astellas Pharma Global Development

University of Michigan
Ann Arbor, MI United States
  Connect »

Astellas Pharma Global Development

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Astellas Pharma Global Development

Medical College of Wisconsin
Milwaukee, WI United States
  Connect »

Astellas Pharma Global Development

Virginia G Piper Cancer Center
Scottsdale, AZ United States
  Connect »

Astellas Pharma Global Development

University of Florida
Gainesville, FL United States
  Connect »

Astellas Pharma Global Development

Indiana Blood and Marrow Transplant
Indianapolis, IN United States
  Connect »

Astellas Pharma Global Development

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Astellas Pharma Global Development

Karmanos Cancer Center
Detroit, MI United States
  Connect »

Astellas Pharma Global Development

Texas Transplant Institute
San Antonio, TX United States
  Connect »

Astellas Pharma Global Development

Site GB44005
Nottingham, United Kingdom
  Connect »

Astellas Pharma Global Development

University of California San Francisco
San Francisco, CA United States
  Connect »

Astellas Pharma Global Development

Emory University
Atlanta, GA United States
  Connect »

Astellas Pharma Global Development

Loyola University Medical Center
Maywood, IL United States
  Connect »

Astellas Pharma Global Development

Northwestern Memorial Hospital
Chicago, IL United States
  Connect »

Astellas Pharma Global Development

University of Pennsylvania
Philadelphia, PA United States
  Connect »

Astellas Pharma Global Development

Medical University of South Carolina
Charleston, SC United States
  Connect »

Astellas Pharma Global Development

Huntsman Cancer Institute
Salt Lake City, UT United States
  Connect »

Astellas Pharma Global Development

Site GB44001
Sutton, United Kingdom
  Connect »

Astellas Pharma Global Development

University of Miami
Miami, FL United States
  Connect »

Astellas Pharma Global Development

Mayo Clinic
Rochester, MN United States
  Connect »

Astellas Pharma Global Development

University of North Carolina
Chapel Hill, NC United States
  Connect »

Astellas Pharma Global Development

Wake Forest Baptist Health
Winston-Salem, NC United States
  Connect »

Astellas Pharma Global Development

Oncology Hematology Care, Inc
Cincinnati, OH United States
  Connect »

Astellas Pharma Global Development

Cleveland Clinic
Cleveland, OH United States
  Connect »

Astellas Pharma Global Development

Vanderbilt University Medical Center
Nashville, TN United States
  Connect »

Astellas Pharma Global Development

University of Virginia
Charlottesville, VA United States
  Connect »

Astellas Pharma Global Development

Oregon Health and Science University
Portland, OR United States
  Connect »

Astellas Pharma Global Development

Site GB44002
Manchester, United Kingdom
  Connect »

Astellas Pharma Global Development

Augusta University
Augusta, GA United States
  Connect »

Astellas Pharma Global Development

Virginia Commonwealth University
Richmond, VA United States
  Connect »

Astellas Pharma Global Development

Site FR33009
Marseille, France
  Connect »

Astellas Pharma Global Development

Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »

Astellas Pharma Global Development

Weill Cornell Medical Center
New York, NY United States
  Connect »

Astellas Pharma Global Development

Intermountain BMT
Salt Lake City, UT United States
  Connect »

Astellas Pharma Global Development

Site DE49002
Düsseldorf, Germany
  Connect »

Astellas Pharma Global Development

Site DE49004
Münster, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.